Monitoring Tissue Coagulation During Thermoablative Treatment by Using a Novel Magnetic Resonance Imaging Contrast Agent

• Published in: Investigative radiology Vol. 39; no. 11; pp. 661 - 665
• Main Authors: Vogel, Mika W, Entius, Cornelius A. C, Pattynama, Peter M. T
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins, Inc 01-11-2004
• Subjects: Animals; Contrast Media; Feasibility Studies; Female; Gadolinium; Gadolinium DTPA; Hyperthermia, Induced; Magnetic Resonance Imaging - methods; Muscle, Skeletal; Organometallic Compounds; Statistics, Nonparametric; Swine
• ISSN: 0020-9996; 1536-0210
• DOI: 10.1097/00004424-200411000-00003

INTRODUCTION:We tested the feasibility of using a novel contrast agent, MS-325, as a marker of coagulating tissue during thermoablative treatment.
MATERIALS AND METHODS:In vivo, we created coagulated lesions in porcine muscle tissue under 3 different conditionsMS-325 (n = 5), gadolinium-DTPA (n = 5), or no contrast agent (n = 9) present during laser thermoablation. At the same time, we performed continuous T1-weighted magnetic resonance imaging at 1.5 T. We quantified the change in signal intensity during treatment expressed as relative enhancement, and compared the 3 groups by using Mann–Whitney analysis.
RESULTS:MS-325 resulted in a more than 3.2-fold increase in relative enhancement over the gadolinium-DTPA and noncontrast control groups (P < 0.008).
CONCLUSION:MS-325 appears to be a valid marker for coagulating tissue and significantly increased relative enhancement of the treated lesions when compared with both Gd-DTPA and noncontrast-enhanced conditions. MS-325 thus has potential for monitoring of thermoablative treatment.